Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SingHealth, Aussie Sirtex Ink Research Collaboration For mAb-delivering Nanoparticles

This article was originally published in PharmAsia News

Executive Summary

SingHealth’s National Cancer Center has signed a research pact with Australia-listed oncology company Sirtex to begin preclinical work on a novel biologic targeted cancer therapy to determine if the method shows efficacy in removing microscopic “tumor islands” left after surgery.


Related Content

Sir-Spheres Selective Radiation Therapy Approvable For Liver Cancer - Panel


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts